Skip to content

Sarcopenia, anabolic and catabolic hormones in liver cirrhosis (SACL)

Sarcopenia, anabolic and catabolic hormones in liver cirrhosis (SACL) - MLD-DSS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00034917
Enrollment
400
Registered
2024-10-18
Start date
2019-06-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K70.0 K76.0

Interventions

Group 1: The project aims to: quantify 78 serum metabolites from 126 patients with Metabolic-Associated Steatotic Liver Disease and statistically compare them with the quantification of these metabol

Sponsors

Medizinischen Hochschule Brandenburg (MHB) Theodor Fontane
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Healthy subjects, who are working at University Hospital Ruppin-Brandenburg and University Hospital Brandenburg an der Havel. All subjects must be of legal age. Patients of legal age with non-alcoholic and alcoholic liver diseases (liver cirrhosis). 3. Healthy subjects must written declaration of consent (for healthy subjects and patients) must be available.

Exclusion criteria

Exclusion criteria: 1. Healthy subjects and patients who do not meet the inclusion criteria or who their Withdraw consent to participate in the study. 2. Healthy subjects and patients with pregnancies, orthopedic diseases or injuries, traumatic conditions after amputation of extremities, neurologic paresis and central dizziness.

Design outcomes

Primary

MeasureTime frame
The aim of this study is: to address the question whether the quantification of metabolites is useful to discriminate between 126 healthy subjects and patients with specific livere diseases (28 patients with Metabolic-Associated Steatotic Liver Disease (MASLD) or 98 patients with MASLD or increased alcohol intake (MetALD) and Alcohol-Associated Liver Disease (ALD). Additionally, we investigate whether the quantification of metabolites is useful to discriminate between 28 patients with Metabolic-Associated Steatotic Liver Disease (MASLD) and 98 patients with MASLD or increased alcohol intake (MetALD) and Alcohol-Associated Liver Disease (ALD).

Secondary

MeasureTime frame
To comparatively examine, whether in 98 patients with MetALD and ALD the quantification of metabolites is able to discriminate according to currently applied criterias in clinical diagnostics. These criterias are: 1. Child-Pugh Score, 2. Meld Score, 3. HE Score, 4. Ascites, 5. INR Score, 6. BTR Score.

Countries

Germany

Contacts

Public ContactWerner Dammermann

Medizinischen Hochschule Brandenburg (MHB) Theodor Fontane

werner.dammermann@mhb-fontane.de03381411671

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026